{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:45:47Z","timestamp":1793313947621,"version":"4.5.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:00:00Z","timestamp":1694131200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.jgar.2023.08.022","type":"journal-article","created":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T21:36:34Z","timestamp":1694554594000},"page":"93-100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["In vitro activity of ceftazidime-avibactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa from sub-Saharan Africa: ATLAS Global Surveillance Program 2017\u20132021"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7356-1851","authenticated-orcid":false,"given":"Mark G.","family":"Wise","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Karlowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith A.","family":"Hackel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Amine","family":"Harti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bontle M.E.","family":"Ntshole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva Njeri","family":"Njagua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Oladele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Samuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1722-4524","authenticated-orcid":false,"given":"Shameema","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannette","family":"Wadula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6981-389X","authenticated-orcid":false,"given":"Warren","family":"Lowman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Busisani W.","family":"Lembede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel F.","family":"Sahm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2023.08.022_bib0001","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2023.08.022_bib0002","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1093\/cid\/ciy378","article-title":"Difficult-to-treat resistance in Gram-negative bacteremia at 173 US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents","volume":"67","author":"Kadri","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2023.08.022_bib0003","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.ijantimicag.2018.05.019","article-title":"Review and mapping of carbapenem-resistant Enterobacteriaceae in Africa: using diverse data to inform surveillance gaps","volume":"52","author":"Mitang","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2023.08.022_bib0004","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1128\/AAC.02286-15","article-title":"Activity of ceftazidime-avibactam against extended-spectrum- and AmpC \u03b2-lactamase-producing Enterobacteriaceae collected in the INFORM global surveillance study from 2012 to 2014","volume":"60","author":"Karlowsky","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2023.08.022_bib0005","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1128\/AAC.00220-16","article-title":"In vitro susceptibility of global surveillance isolates of Pseudomonas aeruginosa to ceftazidime-avibactam (INFORM 2012 to 2014)","volume":"60","author":"Nichols","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2023.08.022_bib0006","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1093\/jac\/dkz456","article-title":"In vitro activity of ceftazidime\/avibactam against isolates of carbapenem-non-susceptible Enterobacteriaceae collected during the INFORM global surveillance programme (2015\u20132017)","volume":"75","author":"Spiliopoulou","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2023.08.022_bib0007","series-title":"Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically","year":"2018"},{"key":"10.1016\/j.jgar.2023.08.022_bib0008","series-title":"Performance Standards for Antimicrobial Susceptibility Testing","year":"2022"},{"key":"10.1016\/j.jgar.2023.08.022_bib0009","unstructured":"EUCAST breakpoint tables for interpretation of MICs and zone diameters. Version 12.0, January 2022. http:\/\/www.eucast.org\/clinical_breakpoints\/."},{"key":"10.1016\/j.jgar.2023.08.022_bib0010","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jgar.2015.05.005","article-title":"Antimicrobial resistance and resistance mechanisms of Enterobacteriaceae in ICU and non-ICU wards in Europe and North America: SMART 2011\u20132013","volume":"3","author":"Lob","year":"2018","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2023.08.022_bib0011","unstructured":"EUCAST breakpoints in brackets. December 2021. http:\/\/www.eucast.org\/clinical_breakpoints_and_dosing\/breakpoints_in_brackets."},{"key":"10.1016\/j.jgar.2023.08.022_bib0012","doi-asserted-by":"crossref","first-page":"6248","DOI":"10.1128\/AAC.00825-15","article-title":"Mutations in \u03b2-lactamase AmpC increase resistance of Pseudomonas aeruginosa isolates to antipseudomonal cephalosporins","volume":"59","author":"Berrazeg","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2023.08.022_bib0013","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1128\/AAC.00124-21","article-title":"Emergence of resistance to ceftazidime-avibactam in a Pseudomonas aeruginosa isolate producing derepressed blaPDC in a hollow-fiber infection model","volume":"65","author":"Drusano","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2023.08.022_bib0014","doi-asserted-by":"crossref","first-page":"628","DOI":"10.3390\/antibiotics11050628","article-title":"Resistance to ceftazidime\/avibactam, meropenem\/vaborbactam and imipenem\/relebactam in Gram-negative MDR bacilli: molecular mechanisms and susceptibility testing","volume":"11","author":"Gaibani","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.jgar.2023.08.022_bib0015","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.3390\/antibiotics11111456","article-title":"Suboptimal concentrations of ceftazidime\/avibactam (CAZ-AVI) may select for CAZ-AVI resistance in extensively drug-resistant Pseudomonas aeruginosa: in vivo and in vitro evidence","volume":"11","author":"Lopez-Montesinos","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.jgar.2023.08.022_bib0016","doi-asserted-by":"crossref","first-page":"e487","DOI":"10.1093\/cid\/ciaa084","article-title":"Impact of difficult-to-treat resistance in Gram-negative bacteremia on mortality: retrospective analysis of nationwide surveillance data","volume":"71","author":"Huh","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2023.08.022_bib0017","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1093\/cid\/ciaa381","volume":"72","author":"Karlowsky","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2023.08.022_bib0018","doi-asserted-by":"crossref","first-page":"dlab067","DOI":"10.1093\/jacamr\/dlab067","article-title":"In vitro activity of ceftazidime-avibactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa from Middle Eastern and African countries: ATLAS global surveillance programme 2015-18","volume":"3","author":"Karlowsky","year":"2021","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.jgar.2023.08.022_bib0019","doi-asserted-by":"crossref","first-page":"ofz505","DOI":"10.1093\/ofid\/ofz505","article-title":"Prognostic utility of the new definition of difficult-to-treat resistance among patients with Gram-negative bloodstream infections","volume":"6","author":"Giannelli","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2023.08.022_bib0020","unstructured":"Allergan, Inc. AVYCAZ\u00ae package insert. 2022. https:\/\/www.allergan.com\/assets\/pdf\/avycaz_pi."},{"key":"10.1016\/j.jgar.2023.08.022_bib0021","unstructured":"Pfizer Pharmaceuticals. Zavicefta summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zavicefta-epar-product-information_en.pdf [accessed 24 February 2023]."},{"key":"10.1016\/j.jgar.2023.08.022_bib0022","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1093\/cid\/ciaa1478","volume":"72","author":"Tamma","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2023.08.022_bib0023","first-page":"453","article-title":"Best practices: appropriate use of the new \u03b2-lactam\/\u03b2-lactamase inhibitor combinations, ceftazidime-avibactam and ceftolozane-tazobactam in South Africa","volume":"37","author":"Brink","year":"2022","journal-title":"S Afr J Infect Dis"},{"key":"10.1016\/j.jgar.2023.08.022_bib0024","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00846-21","article-title":"Evaluation of susceptibility testing methods for aztreonam and ceftazidime-avibactam combination therapy on extensively drug-resistant Gram-negative organisms","volume":"65","author":"Khan","year":"2021","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716523001558?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716523001558?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T10:01:33Z","timestamp":1761991293000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716523001558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":24,"alternative-id":["S2213716523001558"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2023.08.022","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of ceftazidime-avibactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa from sub-Saharan Africa: ATLAS Global Surveillance Program 2017\u20132021","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2023.08.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}